SEC Filing | Endo International plc

View:

Download DOC

Download PDF

Download XLS

425

Filed by Endo International plc (Commission File No. 001-36326)

pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934

Subject Company: Auxilium Pharmaceuticals, Inc.

(Commission File No. 001-36628)

The following slides were used during Endo’s presentation of earnings for the third quarter of 2014 on November 5, 2014:

Endo International plc

Q3 2014 Earnings Report

November 5, 2014

ADDITIONAL INFORMATION

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a

proposed business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc. ("Auxilium").

furtherance

this

proposed

transaction,

Endo

and

Auxilium

intend

file

one

registration

statements,

prospectuses,

proxy

statements or other documents with the U.S. Securities and Exchange Commission ("SEC"). This communication is not a substitute for

any

registration

statement,

prospectus,

proxy

statement

other

document

Endo

and/or

Auxilium

file

with

the

SEC

connection

with

the proposed transaction. INVESTORS AND SECURITY HOLDERS OF AUXILIUM ARE URGED TO READ THE REGISTRATION

STATEMENT,

PROSPECTUS,

PROXY

STATEMENT

AND

OTHER

DOCUMENTS

FILED

WITH

THE

SEC

CAREFULLY

THEIR

ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED

TRANSACTION. The definitive proxy statement (when available) will be mailed to stockholders of Auxilium. Investors and security

holders will be able to obtain free copies of these documents (when available) and other documents filed with the SEC by Endo through

the

web

site

maintained

the

SEC

http://www.sec.gov.

CERTAIN INFORMATION REGARDING PARTICIPANTS

Additional Information

All trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of their respective

owners. XIAFLEX®, Testim®, TESTOPEL®, STENDRA®, edex®, Osbon® ErecAid®, STRIANT®, Theo24®, Semprex®-D, dilatrate®-

SR and robaxin® and the related logos are the property of Auxilium. All other trademarks, service marks, trade names, product names

and logos appearing in this presentation are the property of Endo

Endo and Auxilium and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of

proxies from Auxilium stockholders with respect to the proposed transaction under the rules of the SEC. Security holders may obtain

information regarding the names and interests of Endo's directors and executive officers in Endo Health Solutions Inc.'s ("EHSI") Annual

Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 3, 2014, and Endo's proxy

statement for the 2014 Annual General Meeting of Shareholders, which was filed with the SEC on April 29, 2014. Security holders may

obtain information regarding the names and interests of Auxilium's directors and executive officers in Auxilium's Annual Report on Form

10-K for the year ended December 31, 2013, which was filed with the SEC on February 28, 2014, Auxilium's proxy statement for the

2014 Annual Meeting of Stockholders, which was filed with the SEC on April 10, 2014, and the materials that will be filed with the SEC

in connection with the proposed transaction. These documents can be obtained free of charge from the sources indicated above.

Additional information regarding the interests of these participants in the proxy solicitation and a description of their direct and indirect

interests, by security holdings or otherwise, will also be included in the proxy statement and other relevant materials to be filed with the

SEC when they become available.

Forward Looking Statements; Non-GAAP Financial Measures

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

and Canadian securities legislation. Statements including words such as “believes,”

“expects,”

“anticipates,”

“intends,”

“estimates,”

“plan,”

“will,”

“may,”

“look forward,”

“intend,”

“guidance,”

“future”

or similar expressions are forward-looking

statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these

forward-looking statements involve risks and uncertainties. Although Endo believes that these forward-looking statements and

information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any

other forward looking statements or information in this news release. Investors should note that many factors, as more fully

described in the documents filed by Endo with securities regulators in the United States and Canada including under the caption

“Risk Factors”

in Endo’s and EHSI’s Form 10-K, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange

Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval (“SEDAR”) and as

otherwise enumerated herein or therein, could affect Endo’s future financial results and could cause Endo’s actual results to differ

materially from those expressed in forward-looking statements contained in EHSI’s Annual Report on Form 10-K. The forward-

looking statements in this presentation are qualified by these risk factors. These are factors that, individually or in the aggregate,

could cause our actual results to differ materially from expected and historical results. Endo assumes no obligation to publicly

update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as

may be required under applicable securities law.

This presentation may refer to non-GAAP financial measures, including adjusted diluted EPS, that are not prepared in accordance

with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures

used by other companies. Investors are encouraged to review Endo’s current report on Form 8-K filed with the SEC for Endo’s

reasons for including those non-GAAP financial measures in this presentation. Reconciliation of non-GAAP financial measures to the

nearest comparable GAAP amounts have been provided within the appendix at the end of this presentation.

Today’s Agenda

Review of Recent Accomplishments

Review of Q3 2014 Financial Results

Update to 2014 Financial Guidance

Q&A

Progress on Near-Term Strategic Priorities

Deploying capital to accretive, value-creating opportunities

•

Announced agreement to acquire Auxilium Pharmaceuticals

•

Closed acquisitions of Grupo Farmaceutico Somar and DAVA Pharmaceuticals

Enhancing operational focus on organic growth drivers

•

Delivering double-digit organic growth in U.S. Generics

•

Voltaren®

Gel prescription demand trends remain strong

•

Launched Travelan®

and Veregen®

in Canada

•

Fortesta®

Gel AG launch driving increased franchise sales

Sharpening R&D focus on near-term opportunities

•

Focused on filing NDA for BEMA buprenorphine by late-2014 or early-2015

•

Completed full-year objective of 8 ANDA filings by U.S. Generics business

•

AMS

announced

positive

top-line

results

for

the

investigational

TOPAS™

system

Meeting our Financial Targets

•

Raising 2014 Revenue and Adjusted EPS Financial Guidance based on solid operating results

and progress on near-term priorities

Endo

Acquire

Auxilium

Transaction

Summary

Creates leading specialty healthcare company with expanded

platform for future growth

Significant opportunity for value creation

Expected to be immediately accretive post-close and substantially accretive

long-term

Base-case exceeds key M&A model hurdle rates

Auxilium products expected to produce sustained double-digit revenue

growth for Auxilium

Expected annual run rate synergies of up to $175 million by the

first year after closing

Synergies inclusive of Auxilium’s previously announced $75 million reduction

in annual operating expenses

Expected closing in the first half of 2015, subject to regulatory

approval, Auxilium stockholder approval and other customary

closing conditions

Expected to significantly enhance Endo's branded pharmaceutical business with the

addition of Auxilium's leading men's health products and development portfolio

Designed to accelerate growth and maximize value of Auxilium’s products by leveraging

strengths of combined company

Enhances the long-term organic growth for combined branded pharmaceutical business

Expands R&D capabilities and development programs

Compelling Strategic and Financial Rationale

Creating benefits for both Endo and Auxilium shareholders,

as well as for patients, customers and employees

Generates significant synergy opportunities in addition to Auxilium’s announced

restructuring

Creates company with enhanced financial flexibility, proven M&A platform and

established corporate structure

Aligned with Endo’s strategy of pursuing accretive, value-creating growth opportunities

Summary of Q3 2014

Financial Results and

Organic Growth

Q3 and YTD 2014 Financial Performance

(US $M except EPS)

Q3 2014

Y/Y

Growth %

YTD 2014

Y/Y

Growth %

Revenue

$764

16%

$2,077

Reported (GAAP) EPS

($1.64)

($4.62)

Adjusted Net Income

$182

13%

$490

Adjusted Diluted EPS

$1.15

(14%)

$3.14

(18%)

Drive

Organic

Growth

–

U.S.

Branded

Pharmaceuticals

U.S. Branded Pharmaceuticals

Core Revenue Growth vs. PY

Core portfolio of products on-

track to deliver 2014 objective for

growth

Expect to submit NDA for BEMA®

buprenorphine by end of 2014 or

early 2015

Successful management of

LIDODERM LOE

Fortesta®

Gel AG launch

exceeding expectations

Core Excludes LIDODERM®,

Actavis Royalty, OPANA®

11%

YTD 2014*

Q3 2014*

Sumavel® DosePro® is excluded for comparison purposes

Drive

Organic

Growth

–

U.S.

Generic

Pharmaceuticals

Base business growth of 13% in Q3

2014

$111m of new revenues in Q3 2014

drive total revenue growth of 74%

for U.S. Generics

Continued success for Lidoderm AG

launch

Acquisitions of Boca and DAVA add

to significant growth

Underlying excludes sales of Lidoderm

AG, Boca Pharmacal and DAVA

Pharmaceuticals products

U.S. Generic Pharmaceuticals

Q3 Core Revenue Growth vs. PY

13%

74%

Underlying

Total

Drive

Organic

Growth

Devices

On-track to return to organic

revenue growth and expand

operating margins

BPH Therapy business leading

growth

sales

GreenLight

fiber continue to increase

Men’s Health business provides

stable/growing core

Managing impact of market

decline in Women’s Health (WH)

Devices Revenue Growth

Versus Prior Year

~Flat

FY 2013

FY 2013 less WH

YTD 2014

YTD 2014 less WH

Drive Organic Growth –

International Pharmaceuticals

2014 performance on-track with internal expectations

Paladin business development continues to add future growth

drivers

Launches of Travelan®

and Veregen®

in Canada

Base Paladin business delivering solid performance

Integration of Somar on-track

Norbert Oppitz, Regional President, Latin America, Africa and Export Markets,

joined on October 1, 2014

Expansion opportunities for Somar product portfolio being explored

Financial and IT system consolidation successfully completed

Initiated process to acquire outstanding shares of Litha

Q3 2014 Financial Update

and Full-Year Guidance

Q3 and YTD 2014 Segment Revenues

(US $M)

Q3 2014

Y/Y

Growth %

YTD 2014

Y/Y

Growth %

U.S. Branded Pharmaceuticals

$241

(34%)

$724

(36%)

U.S. Generic Pharmaceuticals

$319

74%

$803

51%

Devices

$110

(1%)

$359

~Flat

International Pharmaceuticals

$94

$191

Total

$764

16%

$2,077

Q3 and YTD 2014 Income Statement (Adjusted)

($M except Shares and EPS)

Q3 2013

Q3 2014

Y/Y Change

Favorable /

(Unfavorable)

YTD 2013

YTD 2014

Y/Y Change

Favorable /

(Unfavorable)

Revenues

$661

$764

16%

$2,032

$2,077

Gross Margin

$448

$479

$1,389

$1,336

(4%)

% of Revenues

67.7%

62.8%

68.4%

64.3%

Operating Expenses

$190

$187

$639

$552

14%

% of Revenues

28.7%

24.4%

31.5%

26.6%

Operating Income

$258

$293

14%

$750

$784

% of Revenues

39.0%

38.3%

36.9%

37.7%

Tax Rate (Continuing Ops)

27.8%

21.6%

620 bps

29.5%

22.7%

670 bps

Adjusted Net Income

$161

$182

13%

$450

$490

Adjusted EPS

$1.34

$1.15

(14%)

$3.85

$3.14

(18%)

Adjusted Diluted Shares (M)

120.3

159.0

116.9

155.9

Reported (GAAP) EPS

$0.33

($1.64)

$0.77

($4.62)

2014 Financial Guidance

Measure

Prior Guidance

Updated 2014 Guidance

Revenues

$2.78B -

$2.86B

$2.80B -

$2.88B

Adjusted Gross Margin

63% to 65%

63.5% to 64.5%

Adjusted Operating

Expenses

Year-over-year mid-to-high digit

percentage decrease

Year-over-year mid-to-high digit

percentage decrease

Adjusted Interest Expenses

~$220M

Reported (GAAP) Loss per

$1.56 to $1.36

$3.95 to $3.80

Adjusted Diluted EPS

$4.00 to $4.20

$4.10 to $4.25

Adjusted Effective Tax Rate

23% to 24%

Approximately 23%

Weighted Average Diluted

Shares Outstanding

Approximately 157M

Progress on Near-Term Strategic Priorities

Deploying capital to accretive, value-creating opportunities

•

Announced agreement to acquire Auxilium Pharmaceuticals

•

Closed acquisitions of Grupo Farmaceutico Somar and DAVA Pharmaceuticals

Enhancing operational focus on organic growth drivers

•

Delivering double-digit organic growth in U.S. Generics

•

Voltaren®

Gel prescription demand trends remain strong

•

Launched Travelan®

and Veregen®

in Canada

•

Fortesta®

Gel AG launch driving increased franchise sales

Sharpening R&D focus on near-term opportunities

•

Focused on filing NDA for BEMA buprenorphine by late-2014 or early-2015

•

Completed full-year objective of 8 ANDA filings by U.S. Generics business

•

AMS

announced

positive

top-line

results

for

the

investigational

TOPAS™

system

Meeting our Financial Targets

•

Raising 2014 Revenue and Adjusted EPS Financial Guidance based on solid operating results

and progress on near-term priorities

Appendix

Reconciliation of Non-GAAP Measures

Three Months Ended September 30, 2014

(unaudited)

Actual

Reported

(GAAP)

Adjustments

Non-GAAP

Adjusted

REVENUES

763,938

—

763,938

COSTS AND EXPENSES:

Cost of revenues

379,199

(94,751)

(1)

284,448

Selling, general and administrative

205,260

(45,357)

(2)

159,903

Research and development

30,918

(4,300)

(3)

26,618

Litigation-related and other contingencies, net

473,338

(473,338)

(4)

—

Acquisition-related and integration items

6,932

(6,932)

(5)

—

OPERATING (LOSS) INCOME

(331,709)

624,678

292,969

INTEREST EXPENSE, NET

61,949

(1,992)

(6)

59,957

LOSS ON EXTINGUISHMENT OF DEBT

2,027

(2,027)

(7)

—

OTHER (INCOME) EXPENSE, NET

(4,871)

5,729

(8)

858

(LOSS) INCOME FROM CONTINUING OPERATIONS BEFORE

INCOME TAX

(390,814)

622,968

232,154

INCOME TAX

(138,765)

188,986

(9)

50,221

(LOSS) INCOME FROM CONTINUING OPERATIONS

(252,049)

433,982

181,933

DISCONTINUED OPERATIONS, NET OF TAX

—

CONSOLIDATED NET (LOSS) INCOME

(252,049)

433,982

181,933

Less: Net income (loss) attributable to

noncontrolling interests

(369)

(10)

(334)

NET (LOSS) INCOME ATTRIBUTABLE TO ENDO

INTERNATIONAL PLC

(252,084)

434,351

182,267

DILUTED EARNINGS PER SHARE DATA ATTRIBUTABLE TO

ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS:

Continuing operations

(1.64)

1.15

Discontinued operations

—

DILUTED (LOSS) EARNINGS PER SHARE

(1.64)

1.15

DILUTED WEIGHTED AVERAGE SHARES

153,309

158,975

Notes to reconciliation of our GAAP statements of operations to our

adjusted statements of operations:

To exclude amortization of commercial intangible assets related to

developed technology of $68,293 and a fair value step-up in inventory

of $17,364 and accruals for milestone payments to partners of $9,094.

To exclude certain separation benefits and other costs incurred in

connection with continued efforts to enhance the company's

operations of $8,284, amortization of intangible assets of $2,513, mesh

litigation-related defense costs of $10,588, a charge for an additional

year of the branded prescription drug fee in accordance with IRS

regulations issued in the third quarter of 2014 of $24,972 and an

adjustment to the accrual for excise tax payments of $(1,000).

To exclude milestone payments to partners of $4,354 and adjustments

to accruals for other costs incurred in connection with continued

efforts to enhance the company's operations of $(54).

To exclude the impact of net charges primarily for mesh-related

product liability.

To exclude acquisition and integration costs of $6,932 associated with

the Paladin, Boca and other acquisitions.

To exclude additional non-cash interest expense related to our 1.75%

Convertible Senior Subordinated Notes.

To exclude the net loss on extinguishment of debt in connection with

various refinancing and note repurchase activity.

To exclude adjustments to the gain on sale of certain early-stage drug

discovery and development assets of $(150), foreign currency impact

related to the remeasurement of intercompany debt instruments of

$(5,740) and other miscellaneous expense of $161.

Primarily to reflect the cash tax savings from acquired tax attributes

and the tax effect of the pre-tax adjustments above at applicable tax

rates.

10.

To exclude the impact of the portion of certain of the above

adjustments attributable to noncontrolling interests.

Reconciliation of Non-GAAP Measures

Three Months Ended September 30, 2013

(unaudited)

Actual

Reported

(GAAP)

Adjustments

Non-GAAP

Adjusted

REVENUES

661,319

—

661,319

COSTS AND EXPENSES:

Cost of revenues

257,836

(44,458

)

(1)

213,378

Selling, general and administrative

191,362

(27,994

)

(2)

163,368

Research and development

36,687

(10,005

)

(3)

26,682

Litigation-related and other contingencies

30,895

(30,895

)

(4)

—

Asset impairment charges

807

(807

)

(5)

—

Acquisition-related and integration items

1,493

(1,493

)

(6)

—

OPERATING INCOME

142,239

115,652

257,891

INTEREST EXPENSE, NET

43,081

(5,704

)

(7)

37,377

OTHER INCOME, NET

(14,672)

14,628

(8)

(44

)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME

TAX

113,830

106,728

220,558

INCOME TAX

44,655

16,744

(9)

61,399

INCOME FROM CONTINUING OPERATIONS

69,175

89,984

159,159

DISCONTINUED OPERATIONS, NET OF TAX

(14,560)

30,506

(10)

15,946

CONSOLIDATED NET INCOME

54,615

120,490

175,105

Less: Net income attributable to noncontrolling

interests

14,392

—

14,392

NET INCOME ATTRIBUTABLE TO ENDO INTERNATIONAL PLC

40,223

120,490

160,713

DILUTED EARNINGS PER SHARE DATA ATTRIBUTABLE TO

ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS:

Continuing operations

0.58

1.32

Discontinued operations

(0.25)

0.02

DILUTED EARNINGS PER SHARE

0.33

1.34

DILUTED WEIGHTED AVERAGE SHARES

120,261

To exclude amortization of commercial intangible assets related to

marketed products of $42,482, certain separation benefits and

other costs incurred in connection with continued efforts to

enhance the company's operations of $(24) and accruals for

milestone payments to partners of $2,000.

To exclude certain separation benefits and other costs incurred in

connection with continued efforts to enhance the company’s

operations of $11,784, amortization of customer relationships of

$2,505 and mesh litigation-related defense costs of $13,705.

To exclude milestone payments to partners of $1,092 and certain

separation benefits and other costs incurred in connection with

continued efforts to enhance the company’s operations of $8,913.

To exclude the impact of charges primarily for mesh-related

product liability.

To exclude asset impairment charges.

To exclude acquisition and integration costs.

To exclude additional non-cash interest expense related to our

1.75% Convertible Senior Subordinated Notes.

To exclude $(14,628) related to patent litigation settlement

income.

Primarily to reflect the cash tax savings from acquired tax

attributes and the tax effect of the pre-tax adjustments above at

applicable tax rates.

To exclude certain items related to the HealthTronics business,

which is reported as Discontinued operations, net of tax.

Notes to reconciliation of our GAAP statements of operations to our

adjusted statements of operations:

10.

Reconciliation of Non-GAAP Measures

Nine Months Ended September 30, 2014

(unaudited)

Actual

Reported

(GAAP)

Adjustments

Non-GAAP

Adjusted

REVENUES

2,077,231

—

2,077,231

COSTS AND EXPENSES:

Cost of revenues

976,899

(236,065)

(1)

740,834

Selling, general and administrative

603,573

(139,912)

(2)

463,661

Research and development

113,772

(25,022)

(3)

88,750

Litigation-related and other contingencies, net

1,135,443

(1,135,443)

(4)

—

Acquisition-related and integration items

71,819

(71,819)

(5)

—

OPERATING (LOSS) INCOME

(824,275

)

1,608,261

783,986

INTEREST EXPENSE, NET

167,528

(11,307)

(6)

156,221

LOSS ON EXTINGUISHMENT OF DEBT

31,712

(31,712)

(7)

—

OTHER INCOME, NET

(17,731

)

9,579

(8)

(8,152)

(LOSS) INCOME FROM CONTINUING OPERATIONS BEFORE

INCOME TAX

(1,005,784

)

1,641,701

635,917

INCOME TAX

(338,592

)

482,970

(9)

144,378

(LOSS) INCOME FROM CONTINUING OPERATIONS

(667,192

)

1,158,731

491,539

DISCONTINUED OPERATIONS, NET OF TAX

2,251

694

(10)

2,945

CONSOLIDATED NET (LOSS) INCOME

(664,941

)

1,159,425

494,484

Less: Net income attributable to noncontrolling interests

2,895

1,575

(11)

4,470

NET (LOSS) INCOME ATTRIBUTABLE TO ENDO

INTERNATIONAL PLC

(667,836

)

1,157,850

490,014

DILUTED EARNINGS PER SHARE DATA ATTRIBUTABLE TO

ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS:

Continuing operations

(4.61

)

3.15

Discontinued operations

(0.01

)

(0.01)

DILUTED (LOSS) EARNINGS PER SHARE

(4.62

)

3.14

DILUTED WEIGHTED AVERAGE SHARES

144,604

155,902

Notes to reconciliation of our GAAP statements of operations to our adjusted

statements of operations:

To exclude amortization of commercial intangible assets related to

developed technology of $186,727, a fair value step-up in inventory of

$40,089 and accruals for milestone payments to partners of $9,249.

To exclude certain separation benefits and other costs incurred in

connection with continued efforts to enhance the company's operations

of $20,652, amortization of intangible assets of $7,546, mesh litigation-

related defense costs of $44,442, offset by insurance recoveries of

$(22,000), a charge for an additional year of the branded prescription

drug fee in accordance with IRS regulations issued in the third quarter of

2014 of $24,972, accruals for excise tax payments of $54,300 and a

charge of $10,000 related to the non-recoverability of certain non-trade

receivables that did not relate to

our core operating activities.

To exclude milestone payments to partners of $25,704 and

adjustments to accruals for other costs incurred in connection with

continued efforts to enhance the company's operations of $(682).

To exclude the impact of net charges primarily for mesh-related

product liability.

To exclude acquisition and integration costs of $71,819 associated

with the Paladin, Boca and other acquisitions.

To exclude additional non-cash interest expense related to our 1.75%

Convertible Senior Subordinated Notes.

To exclude the net loss on extinguishment of debt in connection with

various refinancing and note repurchase activity.

To exclude the net gain on sale of certain early-stage drug discovery and

development assets of $(4,000), foreign currency impact related to the

remeasurement of intercompany debt instruments of $(5,740) and other

miscellaneous expense of $161.

Primarily to reflect the cash tax savings from acquired tax attributes and

the tax effect of the pre-tax adjustments above at applicable tax rates.

10.

To exclude the after-tax adjustment to the previously recorded gain on

sale of the HealthTronics business and certain other sale-related costs.

11.

To exclude the impact of the portion of certain of the above adjustments

attributable to noncontrolling interests.

Reconciliation of Non-GAAP Measures

Nine Months Ended September 30, 2013

(unaudited)

Actual

Reported

(GAAP)

Adjustments

Non-GAAP

Adjusted

REVENUES

2,031,961

—

2,031,961

COSTS AND EXPENSES:

Cost of revenues

785,630

(142,923

)

(1)

642,707

Selling, general and administrative

662,896

(113,080

)

(2)

549,816

Research and development

108,849

(19,187

)

(3)

89,662

Litigation-related and other contingencies

159,098

(159,098

)

(4)

—

Asset impairment charges

4,756

(4,756

)

(5)

—

Acquisition-related and integration items

3,876

(3,876

)

(6)

—

OPERATING INCOME

306,856

442,920

749,776

INTEREST EXPENSE, NET

129,691

(16,816

)

(7)

112,875

LOSS ON EXTINGUISHMENT OF DEBT

11,312

(11,312

)

(8)

—

OTHER (INCOME) EXPENSE, NET

(49,641

)

51,448

(9)

1,807

TAX

215,494

419,600

635,094

INCOME TAX

82,917

104,136

(10)

187,053

INCOME FROM CONTINUING OPERATIONS

132,577

315,464

448,041

DISCONTINUED OPERATIONS, NET OF TAX

(3,248

)

44,264

(11)

41,016

CONSOLIDATED NET INCOME

129,329

359,728

489,057

Less: Net income attributable to noncontrolling interests

38,758

—

38,758

90,571

359,728

450,299

DILUTED EARNINGS PER SHARE DATA ATTRIBUTABLE TO ENDO

INTERNATIONAL PLC ORDINARY SHAREHOLDERS:

Continuing operations

1.13

3.83

Discontinued operations

(0.36

)

0.02

DILUTED EARNINGS PER SHARE

0.77

3.85

DILUTED WEIGHTED AVERAGE SHARES

116,890

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME

Notes to reconciliation of our GAAP statements of operations to our adjusted

statements of operations:

To exclude amortization of commercial intangible assets related to

marketed products of $135,805, certain separation benefits and other

costs incurred in connection with continued efforts to enhance the

company's operations of $1,118 and accruals for milestone payments to

partners of $6,000.

To exclude certain separation benefits and other costs incurred in

connection with continued efforts to enhance the company’s operations of

$70,688, amortization of customer relationships of $7,521 and mesh

litigation-related defense costs of $34,871.

To exclude milestone payments to partners of $5,064 and certain

separation benefits and other costs incurred in connection with continued

efforts to enhance the company’s operations of $14,123.

To exclude the impact of charges primarily for mesh-related product

liability.

To exclude asset impairment charges.

To exclude acquisition and integration costs.

To exclude additional non-cash interest expense related to our 1.75%

Convertible Senior Subordinated Notes.

To exclude the unamortized debt issuance costs written off and recorded

as a loss on extinguishment of debt upon our March 2013 prepayment on

our Term Loan indebtedness as well as upon the amendment and

restatement of our existing credit facility.

To exclude $(50,400) related to patent litigation settlement income and

other income of $(1,048).

10.

Primarily to reflect the cash tax savings from acquired tax attributes and

the tax effect of the pre-tax adjustments above at applicable tax rates.

11.

To exclude certain items related to the HealthTronics business, which is

reported as Discontinued operations, net of tax.

NET INCOME ATTRIBUTABLE TO ENDO INTERNATIONAL PLC

Reconciliation of Non-GAAP Measures

For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s Current Report on Form 8-K filed today with the

Securities and Exchange Commission

Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for the Year Ending

December 31, 2014

Lower End of Range

Upper End of Range

Projected GAAP diluted income per common share

($3.95)

($3.80)

Upfront and milestone-related payments to partners

$0.22

Amortization of commercial intangible assets and fair value inventory step-up

$1.89

$1.35

Basic to Diluted weighted average share count effect

$0.24

Charges for Litigation and other legal matters

$7.48

Interest expense adjustment for non-cash interest related to our 1.75% Convertible

Senior Subordinated Notes and other treasury items

$0.08

Tax effect of pre-tax adjustments at the applicable tax rates and certain other

expected cash tax savings as a result of recent acquisitions

($3.21)

Diluted adjusted income per common share guidance

$4.10

$4.25

The company's guidance is being issued based on certain assumptions including:

•

Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results

•

Includes all completed business development transactions as of November 5, 2014

Acquisition Related, Integration and Restructuring Charges

Endo International plc

Q3 2014 Earnings Report

November 5, 2014